Stockreport

TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet

Ionis Pharmaceuticals, Inc.  (IONS) 
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ionispharma.com
PDF TRYNGOLZA shown to significantly reduce triglycerides and substantially reduce acute pancreatitis events in adults with FCS; a rare, highly debilitating and life-threate [Read more]